Vasogen Announces Sale of Patent Application and Provides Corporate Update



    MISSISSAUGA, ON, Feb. 2 /CNW/ - Vasogen Inc. (NASDAQ:  VSGN; TSX:VAS) today
announced that it has sold a United States patent application and its related
foreign counterparts for US$400,000. This device-based intellectual property
has not been used to date in the Celacade System; however, Vasogen has
retained rights to this technology for any potential use as it relates to its
Celacade System.
    The Company today also announced that it continues to advance the process
associated with its ongoing strategic review and expects to be in a position
to provide a further update to shareholders over the coming weeks. As
previously announced, Vasogen has been reviewing various strategic
alternatives for the purpose of enhancing shareholder value.

    Certain statements in this document constitute "forward-looking
statements" within the meaning of the United States Private Securities
Litigation Reform Act of 1995 and/or "forward-looking information" under the
Securities Act (Ontario). These statements may include, without limitation,
plans to complete a sale, merger, acquisition, or other strategic alternative,
statements regarding the status of development, or expenditures relating to
the Celacade(TM) System or our VP series of drugs including VP015 and VP025,
plans to fund our current activities, statements concerning our partnering
activities, health regulatory submissions, strategy, future operations, future
financial position, future revenues and projected costs. In some cases, you
can identify forward-looking statements by terminology such as "may", "will",
"should", "expects", "plans", "anticipates", "believes", "estimated",
"predicts", "potential", "continue", "intends", "could", or the negative of
such terms or other comparable terminology. We made a number of assumptions in
the preparation of these forward-looking statements. You should not place
undue reliance on our forward-looking statements, which are subject to a
multitude of risks and uncertainties that could cause actual results, future
circumstances or events to differ materially from those projected. These risks
include, but are not limited to, the outcome of our strategic review, securing
and maintaining corporate alliances, the need for additional capital and the
effect of capital market conditions and other factors, including the current
status of our programs, on capital availability, the potential dilutive
effects of any financing and other risks detailed from time to time in our
public disclosure documents or other filings with the Canadian and U.S.
securities commissions or other securities regulatory bodies. Additional risks
and uncertainties relating to our Company and our business can be found in the
"Risk Factors" section of our Annual Information Form and Form 20-F for the
year ended November 30, 2007, as well as in our later public filings,
including our Management's Discussion and Analysis for the quarter ended
August 31, 2008. The forward-looking statements are made as of the date
hereof, and we disclaim any intention and have no obligation or
responsibility, except as required by law, to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.

    %SEDAR: 00001047E          %CIK: 0001042018




For further information:

For further information: Glenn Neumann, Investor Relations, 4 Robert
Speck Parkway, 15th Floor, Mississauga, ON, L4Z 1S1, tel: (905) 817-2004, fax:
(905) 847-6270, www.vasogen.com, investor@vasogen.com

Organization Profile

VASOGEN INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890